InMed Pharmaceuticals Inc Sees Significant Rise

Written by Emily J. Thompson, Senior Investment Analyst

Source: 424B3

Updated: 25 Nov 25

Source: 424B3

InMed Pharmaceuticals Inc has experienced a notable price increase of 12.30% in the regular market. This surge is attributed to the stock crossing above its 5-day simple moving average (SMA), indicating a potential bullish trend.

The broader market context shows major benchmarks trading sideways with mixed signals, suggesting that the movement in INM.O may be more influenced by technical factors rather than external news events. The overall market is tracking at around +0.79% for the session, but INM.O's performance stands out.

Investors often look for technical indicators like moving averages to guide their trading decisions. The crossing above the 5-day SMA can signal a shift in momentum, prompting buying interest among traders.

As the market continues to navigate through uncertain conditions, stocks like InMed Pharmaceuticals Inc that show strong technical signals may attract more attention from investors.

INM

$1.1+Infinity%1D

Analyst Views on INM

About INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

InMed Pharmaceuticals Inc Sees Significant Rise

Analyst Views on INM

About INM

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Trends in Enterprise Network Modernization in Asia Pacific

SpaceX Acquires xAI, Targeting $1.25 Trillion IPO Valuation

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch